ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $751,803 | -46.2% | 35,131 | +1.7% | 0.01% | -50.0% |
| Q1 2023 | $1,396,393 | -15.9% | 34,530 | -3.3% | 0.01% | -23.1% |
| Q4 2022 | $1,661,229 | +89599.2% | 35,710 | 0.0% | 0.01% | -18.8% |
| Q3 2022 | $1,852 | -99.9% | 35,710 | +4.8% | 0.02% | +14.3% |
| Q2 2022 | $1,610,000 | -33.6% | 34,062 | 0.0% | 0.01% | -6.7% |
| Q1 2022 | $2,425,000 | -11.5% | 34,062 | -7.0% | 0.02% | 0.0% |
| Q4 2021 | $2,740,000 | +32.6% | 36,642 | +0.8% | 0.02% | +25.0% |
| Q3 2021 | $2,066,000 | +27.5% | 36,362 | -1.3% | 0.01% | +20.0% |
| Q2 2021 | $1,621,000 | -10.8% | 36,842 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $1,817,000 | +9.1% | 36,842 | -6.9% | 0.01% | -7.7% |
| Q4 2020 | $1,665,000 | -8.1% | 39,552 | 0.0% | 0.01% | -13.3% |
| Q3 2020 | $1,811,000 | +0.7% | 39,552 | +10.4% | 0.02% | -11.8% |
| Q2 2020 | $1,799,000 | -2.4% | 35,832 | 0.0% | 0.02% | -19.0% |
| Q1 2020 | $1,843,000 | -16.8% | 35,832 | 0.0% | 0.02% | +50.0% |
| Q4 2019 | $2,214,000 | -9.5% | 35,832 | -12.0% | 0.01% | -12.5% |
| Q3 2019 | $2,447,000 | -17.5% | 40,732 | +15.8% | 0.02% | -33.3% |
| Q2 2019 | $2,967,000 | +114.8% | 35,160 | +143.2% | 0.02% | +100.0% |
| Q1 2019 | $1,381,000 | +41.6% | 14,460 | +5.1% | 0.01% | +50.0% |
| Q4 2018 | $975,000 | +5.1% | 13,760 | +26.7% | 0.01% | +33.3% |
| Q3 2018 | $928,000 | -14.2% | 10,860 | +16.3% | 0.01% | -14.3% |
| Q2 2018 | $1,082,000 | +43.3% | 9,335 | 0.0% | 0.01% | +40.0% |
| Q1 2018 | $755,000 | +45.8% | 9,335 | +5.7% | 0.01% | +66.7% |
| Q4 2017 | $518,000 | +25.4% | 8,835 | 0.0% | 0.00% | +50.0% |
| Q3 2017 | $413,000 | +59.5% | 8,835 | +22.7% | 0.00% | 0.0% |
| Q2 2017 | $259,000 | -15.1% | 7,200 | -27.3% | 0.00% | -33.3% |
| Q1 2017 | $305,000 | -8.1% | 9,900 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $332,000 | +38.9% | 9,900 | +10.0% | 0.00% | 0.0% |
| Q3 2016 | $239,000 | -9.5% | 9,000 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $264,000 | -11.1% | 9,000 | 0.0% | 0.00% | +50.0% |
| Q4 2015 | $297,000 | -43.3% | 9,000 | -37.9% | 0.00% | -60.0% |
| Q3 2015 | $524,000 | – | 14,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |